Article
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo.
Nature cancer - 1 Oct 2023
Giannakopoulou Eirini, Lehander Madeleine, Virding Culleton Stina, Yang Weiwen, Li Yingqian, Karpanen Terhi, Yoshizato Tetsuichi, Rustad Even H, Nielsen Morten Milek, Bollineni Ravi Chand, Tran Trung T, Delic-Sarac Marina, Gjerdingen Thea Johanne, Douvlataniotis Karolos, Laos Maarja, Ali Muhammad, Hillen Amy, Mazzi Stefania, Chin Desmond Wai Loon, Mehta Adi, Holm Jeppe Sejerø, Bentzen Amalie Kai, Bill Marie, Griffioen Marieke, Gedde-Dahl Tobias, Lehmann Sören, Jacobsen Sten Eirik W, Woll Petter S, Olweus Johanna
Abstract excerpt
Acute myeloid leukemia (AML), the most frequent leukemia in adults, is driven by recurrent somatically acquired genetic lesions in a restricted number of genes. Treatment with tyrosine kinase inhibitors has demonstrated that targeting of prevalent FMS-related receptor tyrosine kinase 3 (FLT3) gain-of-function mutations can provide significant survival benefits for patients, although the efficacy of FLT3...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.